A delegation of Western Australian (WA) companies showcased our State’s growing biomedical industry at the annual BIO International Convention (BIO 2025) in Boston this week.

BIO 2025 is the world’s largest and most comprehensive biotechnology event, bringing together 20,000 industry leaders from around the globe.

The WA delegation was led by Invest and Trade WA’s US-based team, represented by WA’s Investment and Trade Commissioner for the Americas Brianna Peake, Senior Investment and Trade Manager Kim Wiltshire, as well as Dr Tracey Wilkinson and Professor Kevin Pfleger from the WA Life Sciences Innovation Hub.

Organisations taking part in this year’s WA delegation include BioCina, Linear Clinical Research, Lixa, Biotome, SynGenis, ProGenis Pharmaceuticals, PYC Therapeutics, Health Translation Group, the Rare Care Centre, The Kids Research Institute Australia, the University of Western Australia, Curtin University, Brandon Capital and Tenmile. 

The WA delegation also featured alongside other biomedical organisations and government representatives from New South Wales, Victoria, Queensland and South Australia at the BIO 2025 Australia Pavilion.

Organised by national delegation leader MTPConnect, the Australia Pavilion hosted over 200 Australian companies at BIO 2025, highlighting Australia’s key strengths in medical research, clinical trials and advanced manufacturing.

A highlight of the WA delegation program was an event co-hosted by Invest and Trade WA and Invest South Australia, and supported by the Australian Trade and Investment Commission.

Titled Connect to Australia – Linking Global Biotech Organisations to Australia via South Australia and Western Australia, the event brought together Australian and international delegates at BIO 2025 to connect and hear more about the exciting work taking place across the WA and SA biomedical ecosystems.

 The event featured a fireside chat between the President of the American Australian Association, Steven Marshall, and BioCina CEO Mark Womack, who discussed the advantages of operating in Australia and the opportunity for further collaborations with international partners. 

 Other highlights of the week include Linear Clinical Research speaking at an Austrade event on Australian clinical trials capabilities, as well as presentations by Maud Eijkenboom of Lixa and Gareth Baynam of the Rare Care Centre as part of the official BIO 2025 program. 

 Maud Eijkenboom from Lixa spoke about the company’s development of universal anti-microbial resistance breakers in a session on Preparing for the Next Generation in Antimicrobial Resistance: Combining Traditional with Non-Traditional Therapeutic Approaches to Tackle an Ongoing Pandemic.

Meanwhile, Gareth Baynam from the Rare Care Centre profiled the organisation’s work to facilitate clinical trials for children with rare diseases in a session on Ethical and Practical Considerations for Multi-National Rare Disease Clinical Trials.

The week was a resounding success in showcasing WA’s biomedical sector, with strong collaboration across partner organisations and significant engagement by Team WA delegates opening up local access to international partners, customers and investors.

 To learn more about WA’s biomedical industry, visit the WA health and medical life sciences webpage. 

Published on: 26 June 2025